These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10728968)

  • 21. Beta blockers & left ventricular hypertrophy regression.
    George T; Ajit MS; Abraham G
    Indian Heart J; 2010; 62(2):139-42. PubMed ID: 21180305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left ventricular hypertrophy among black hypertensive patients: focusing on the efficacy of angiotensin converting enzyme inhibitors.
    Jaleta GN; Gudina EK; Getinet W
    BMC Res Notes; 2014 Jan; 7():45. PubMed ID: 24444396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
    Mathew J; Sleight P; Lonn E; Johnstone D; Pogue J; Yi Q; Bosch J; Sussex B; Probstfield J; Yusuf S;
    Circulation; 2001 Oct; 104(14):1615-21. PubMed ID: 11581138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of antihypertensive agents on the left ventricle: clinical implications.
    Díez J; González A; López B; Ravassa S; Fortuño MA
    Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention, diagnosis, and treatment of hypertensive heart disease.
    Georgiopoulou VV; Kalogeropoulos AP; Raggi P; Butler J
    Cardiol Clin; 2010 Nov; 28(4):675-91. PubMed ID: 20937450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis.
    Pierdomenico SD; Cuccurullo F
    Am J Hypertens; 2010 Aug; 23(8):876-81. PubMed ID: 20414193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T; Edelstein CL; Chapman AB; Johnson AM; Tison L; Gill EA; Brosnahan GM; Schrier RW
    Nephrol Dial Transplant; 1999 May; 14(5):1113-6. PubMed ID: 10344347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypertension and left ventricular hypertrophy: is drug therapy beneficial?
    Eselin JA; Carter BL
    Pharmacotherapy; 1994; 14(1):60-88. PubMed ID: 8159603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Importance of hypertensive left ventricular hypertrophy in patients with ischemic events of the heart or brain].
    Castilla-Guerra L; Fernández-Moreno MC; Aguilera-Saborido A; Solanella-Soler J
    Hipertens Riesgo Vasc; 2016; 33(2):58-62. PubMed ID: 26669485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects.
    Verdecchia P; Angeli F; Gattobigio R; Sardone M; Pede S; Reboldi GP
    Am J Hypertens; 2006 May; 19(5):493-9. PubMed ID: 16647622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study.
    Gerdts E; Okin PM; Omvik P; Wachtell K; Dahlöf B; Hildebrandt P; Nieminen MS; Devereux RB
    Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):306-12. PubMed ID: 19303268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Management of hypertensive patients with left ventricular hypertrophy].
    Ambrosioni E
    Presse Med; 2002 Oct; 31 Spec No 2():S13-6. PubMed ID: 12355999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.